Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 4/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 4/20 | 0.36 |
| ▸ | CFD | P00746 | 3/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29841210 | 1.00 | ICMT (0.41) | ICMTSERPINE1CFDKRASNPC1 | |
| SCHEMBL18555837 | 0.96 | ICMT (0.42) | ICMTSERPINE1CFDKRASSYK | |
| SCHEMBL29841081 | 0.87 | ICMT (0.38) | ICMTSERPINE1CFDKRAS | |
| SCHEMBL18591239 | 0.87 | ICMT (0.38) | ICMTSERPINE1CFDKRAS | |
| SCHEMBL18611187 | 0.84 | ICMT (0.40) | ICMTCFDSYK | |
| SCHEMBL29546024 | 0.84 | ICMT (0.43) | ICMTSERPINE1CFDCNR1CNR2 | |
| SCHEMBL18555286 | 0.84 | ICMT (0.43) | ICMTSERPINE1CFDCNR1CNR2 | |
| SCHEMBL18611186 | 0.83 | ICMT (0.48) | ICMTSCN9ACNR1CNR2 | |
| SCHEMBL20329709 | 0.82 | ICMT (0.45) | ICMTSERPINE1CFDGAA | |
| SCHEMBL29774760 | 0.82 | ICMT (0.45) | ICMTSERPINE1CFDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| CN-114044800-A | Aryl, heteroaryl and heterocyclic compounds for the treatment of medical disorders | 艾其林医药公司 | 2022-02-15 | — | — | CN | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | ICMT 4435/4885SERPINE1 40/4885CFD 1/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | ICMT 4537/4885SERPINE1 39/4885CFD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.